In collaboration with University of Copenhagen researchers Glycodisplay have developed a novel LongActing GlycoDesign (LAGD) for improving the therapeutic effect of replacement enzymes used to treat lysosomal storage diseases. In the Nature Comms publication it is described how the concept was developed and validated in an animal model of Fabry disease. The major advantages of  the LAGD-enzyme are lower liver uptake, longer circulation time and better targeting to the heart. The heart is poorly treated on current enzyme therapies and many patients die from heart diseases, so the improved LAGD-enzyme will be pursued as a Biobetter for treatment of Fabry disease.

The LAGD concept will be applicable to other lysosomal diseases and Glycodisplay have initiated expansion programme. 

Link to paper: https://www.nature.com/articles/s41467-019-09809-3